Gefitinib, the first approved EGFR-TKI (EGFR—Tyrosine Kinase Inhibitors), was shown to be effective in treating non-small cell lung cancer (NSCLC) patients with EGFR mutations, leading to improved progression-free survival and response rates. Here, EGFR is linked to non-small cell lung carcinoma.